All news

Gilead lifts product sales guidance after strong quarter

Alpha Vantage · Yahoo Finance Singapore · · AI-summarised by FinFlash

Gilead Sciences posted strong revenue and raised full-year product sales guidance, even as projected GAAP losses widen on R&D charges. The company is investing heavily across HIV, liver disease and oncology, with extensive data readouts pointing to a shifting revenue mix. Policy and pricing risks persist, particularly in HIV.

Read original source

GILD company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.